NEW YORK [US]: External Affairs Minister (EAM) S Jaishankar on Monday landed in New York, as part of his US visit, to meet with senior United States officials, and discuss COVID-related cooperation between the two countries.
Ambassador of India to the UN TS Tirumurti received EAM Jaishankar on his first visit to New York after India entered the UN Security Council.
“Privilege to receive External Affairs Minister @DrSJaishankar on his first visit to New York after #India entered the UN #SecurityCouncil on 1 January 2021,” Ambassador Tirumurti tweeted.
Jaishankar’s US visit is slated to last till May 28, the External Affairs Ministry said last week.
The Foreign Minister is expected to meet UN Secretary-General Antonio Guterres in New York and later he will hold discussions with his counterpart Secretary of State Antony Blinken in Washington DC, the ministry said.
He will also be meeting Cabinet members and Senior Officials of the Administration dealing with the bilateral relationship. “External Affairs Minister will have two interactions with business forums on economic and COVID-related cooperation between India and the US,” said the ministry statement.
India is engaged in talks with various US entities involved in Covid vaccines production and is looking forward to procuring and subsequently producing these vaccines. The issue of vaccine procurement is expected to be a key agenda item during Jaishankar’s interaction with US leadership and other stakeholders.
The US has already announced that it is going to distribute 80 million vaccines from its stockpile to countries in need.
With India hit badly by the second Covid wave, efforts of New Delhi will focus on getting the maximum and also looking for tie-ups with vaccine developers to produce in India.
US has a stockpile 60 million Astra Zeneca vaccine doses and also Pfizer, Moderna and Johnson & Johnson COVID-19 vaccines.
US is playing a lead role in assisting India’s fight against the COVID-19 virus. It has already provided large oxygen plants, concentrators, critical medicines like Remdesivir and also raw materials for vaccine manufacturer Serum Institute of India (SII), which is manufacturing Covishield. (Agency)
Follow our WhatsApp channel
